Similarly, glioma patients with MGMT promoter-methylated tumours had a significantly longer PFS (18 vs. 7 months) and OS (29 vs. 12 months) than glioma patients whose tumours lacked MGMT promoter methylation (both P < 0.001). Here, MGMT is linked to glioma.